nach oben

PharmacoEconomics

Erschienen in:

01.12.2010 | Original Research Article

Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance

verfasst von: Klaus Kaier, Uwe Frank

Erschienen in: PharmacoEconomics | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background: The emergence and spread of antimicrobial resistance (AMR) has become a serious public health threat. Rational antibacterial policy, combined with enforcement of infection control practices are key strategies to combat AMR in the hospital setting. Loss of antibacterial activity as a direct result of antibacterial consumption can be modelled via the economic approach of a negative externality.

Objective: To determine the externalities of antibacterial consumption and alcohol-based hand rub use for hand disinfection.

Methods: A simple model was built, combining the results of a recently conducted cost-of-illness study with the results of a multivariate time-series analysis, which determined the impact of antibacterial consumption and alcohol-based hand rub use on the incidence of hospital-acquired infections caused by meticillin-resistant Staphylococcus aureus (MRSA).

Results: Consumption of a single defined daily dose of second-generation cephalosporins, third-generation cephalosporins, fluoroquinolones and lincosamides is associated with a negative externality of about €5, €15, €11 and €12, respectively. In contrast, use of 1 litre of alcohol-based hand rub solution for hand disinfection is associated with a positive externality of about h61. In other words, a single disinfection of the hands (use of 3mL alcohol-based hand rub solution) saves an average €0.18 of the potential cost incurred by MRSA-related infections.

Conclusions: Quantifying the externalities of antibacterial use and alcoholbased hand rub use may lead to changes in prescribing behaviour and increase compliance with hand disinfection. Furthermore, the presented methodology of relating the cost of resistance to specific factors such as antibacterial use and hand disinfection provides information that may be useful for prioritizing prevention methods.

Levy SB. The antibiotic paradox: how miracle drugs are destroying the miracle. New York: Plenum Press, 1992

Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 2005; 5 (2): 115–9PubMed

Aldeyab MA, Monnet DL, Lopez-Lozano JM, et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillinresistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008; 62 (3): 593–600PubMedCrossRef

Kaier K, Hagist C, Frank U, et al. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30 (4): 346–53PubMedCrossRef

Vernaz N, Sax H, Pittet D, et al. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008; 62 (3): 601–7PubMedCrossRef

Elbasha EH. Deadweight loss of bacterial resistance due to overtreatment. Health Econ 2003; 12 (2): 125–38PubMedCrossRef

Phelps CE. Bug/drug resistance: sometimes less is more. Med Care 1989; 27 (2): 194–203PubMedCrossRef

Smith RD, Yago M, Millar M, et al. A macroeconomic approach to evaluating policies to contain antimicrobial resistance: a case study of methicillin-resistant Staphylococcus aureus (MRSA). Appl Health Econ Health Policy 2006; 5 (1): 55–65PubMedCrossRef

Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ 2009; 10 (3): 287–97PubMedCrossRef

10.

Salkind AR, Wright JMPD. Economic burden of adult pharyngitis: the payer’s perspective. Value Health 2008; 11 (4): 621PubMedCrossRef

11.

Kaier K, Frank U. An econometric view of the dynamic relationship between antibiotic consumption, hand disinfection and methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2009; 63 (3): 630–1PubMedCrossRef

12.

Kaier K, Frank U, Hagist C, et al. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother 2009; 63 (3): 609–14PubMedCrossRef

13.

Kritsotakis EI, Christidou A, Roumbelaki M, et al. The dynamic relationship between antibiotic use and the incidence of vancomycin-resistant Enterococcus: time-series modelling of 7-year surveillance data in a tertiary-care hospital. Clin Microbiol Infect 2008; 14 (8): 747–54PubMedCrossRef

14.

Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6 (5): 751–63PubMedCrossRef

15.

Shorr AF. Epidemiology and economic impact of meticillinresistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007; 25 (9): 751–68PubMedCrossRef

16.

Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333 (24): 1618–24PubMedCrossRef

17.

Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis 2004; 10 (8): 1432–41PubMedCrossRef

18.

Paladino JA, Sunderlin JL, Price CS, et al. Economic consequences of antimicrobial resistance. Surg Infect 2002; 3 (3): 259–67CrossRef

19.

Rice DP. Estimating the cost of illness. Am J Public Health 1967; 57 (3): 424CrossRef

20.

Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy 2006; 77 (1): 51–63PubMedCrossRef

21.

Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19 (2): 207–13PubMedCrossRef

22.

Feldstein MS. Review of B.A. Weisbrod’s ‘Economics of public health: measuring the economic impact of diseases’. Econ J 1963; 73 (289): 129–30CrossRef

23.

Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics 1998; 14 (2): 143–8PubMedCrossRef

24.

Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy 1987; 8 (3): 317–23CrossRef

25.

Hodgson TA. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. Health Policy 1989; 11: 57–60PubMedCrossRef

26.

Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536PubMedCrossRef

Titel: Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance
verfasst von: Klaus Kaier
Uwe Frank
Publikationsdatum: 01.12.2010
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 12/2010
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/11535640-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

Acknowledgement

Is There A Role For Pharmacoeconomics In Developing Countries?

A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States

The Economics of a ‘Liberated’ NHS

The Cost Utility of Autologous Chondrocytes Implantation Using ChondroCelect® in Symptomatic Knee Cartilage Lesions in Belgium

The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions